Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.

Ticker(s): INCY

Who's the expert?

Institution: Kids Frist Pediatrics

Chairman of peds at Kids First Pediatrics
Pediatrician with 21 years of experience
Treats 30-60 pediatric RSV patients per season

Interview Goal

To discuss the standard of care and the potential of Opzelura (Ruxolitinib Cream), a topical selective JAK inhibitor for the treatment of mild to moderate atopic dermatitis from Incyte Bio.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.